---
layout: default
title: Ceftobiprole
parent: 僅模型預測 (L5)
nav_order: 140
evidence_level: L5
indication_count: 10
---

# Ceftobiprole
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ceftobiprole: From Bacterial Infections (MRSA) to Rheumatoid Arthritis

## One-Sentence Summary

Ceftobiprole is a broad-spectrum fifth-generation cephalosporin antibiotic developed to treat serious bacterial infections caused by Gram-positive organisms, including methicillin-resistant *Staphylococcus aureus* (MRSA). The TxGNN model predicts it may have activity against **Rheumatoid Arthritis**, with a prediction score of 98.45%. However, **no clinical trials** and **no published literature** currently support this indication — the prediction is entirely computational, and the biological rationale is weak.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Serious bacterial infections (Gram-positive pathogens, including MRSA) |
| Predicted New Indication | Rheumatoid Arthritis |
| TxGNN Prediction Score | 98.45% |
| Evidence Level | L5 |
| Market Status | Not Marketed |
| Number of Licenses | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological information, Ceftobiprole is a fifth-generation cephalosporin antibiotic. Its antimicrobial effect works by inhibiting bacterial cell wall synthesis — specifically by binding to penicillin-binding proteins (PBPs), including PBP2a, the target responsible for MRSA resistance. This makes it effective against a wide range of Gram-positive bacteria, including drug-resistant strains.

Rheumatoid arthritis (RA) is an autoimmune inflammatory joint disease driven by immune dysregulation, not bacterial infection. There is no direct mechanistic bridge between a beta-lactam antibiotic and RA pathophysiology. The only conceivable indirect connection would be through the gut or oral microbiome — for example, *Porphyromonas gingivalis* has been implicated in triggering RA-related immune responses via citrullination of host proteins. However, Ceftobiprole's antibacterial spectrum is directed at Gram-positive organisms (not the anaerobic Gram-negative *P. gingivalis*), and no study has specifically investigated this hypothesis with Ceftobiprole.

The high TxGNN score (98.45%) most likely reflects shared inflammatory pathway nodes in the underlying knowledge graph, rather than true biological plausibility. This prediction is best interpreted as a probable false positive arising from the structural proximity of infection-related and autoimmune-related disease nodes in the graph. It does not provide actionable drug repurposing signal at this stage.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Ceftobiprole is a beta-lactam antibiotic with no established mechanistic connection to rheumatoid arthritis. Despite the high TxGNN prediction score (98.45%), the evidence level is L5 (model prediction only), with zero supporting clinical trials or literature, and the biological rationale is not compelling — this prediction is likely a false positive driven by shared inflammation nodes in the knowledge graph.

**To proceed, the following is needed:**

- Retrieve full mechanism of action data for Ceftobiprole from DrugBank to confirm or rule out any secondary anti-inflammatory properties
- Obtain safety warnings and contraindications from the official package insert before any further evaluation
- Conduct a knowledge graph topology review to understand why this association scored in the top 10 predictions, and whether it reflects a systemic graph bias toward inflammatory conditions
- If the microbiome hypothesis is to be explored, a targeted literature review on beta-lactam antibiotics and RA-associated microbiome changes would be needed
- Consider deprioritising this candidate in favour of Ceftobiprole predictions with stronger mechanistic alignment (e.g., infectious or inflammatory indications with direct antibiotic relevance)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

